A significant proportion of sepsis survivors were also taking other medications, such as mineralocorticoid receptor blockers (MRA; 43%), Sodium-glucose co-transporter-2 (SGLT-2) inhibitors (39%), angiotensin-converting enzyme inhibitor/angiotensin receptor blocker (ACEi/ARB; 18%) and sacubitril/valsartan (25%). This evidence concerns the gene NR3C2 and Sepsis.